Effect of Partial Sleep Deprivation on Immunological System in Peripheral Blood

August 27, 2013 updated by: ayman abu rmaileh, Hadassah Medical Organization

Effect of Sleep Deprivation on Expression of T Cell Markers in Peripheral Blood of Medical Residents

Sleep deprivation was found to affect many organs including the immune system and predisposing for various health consequences including diabetes hypertension infections and increase in neoplastic diseases.

Subjects will be evaluated for immune parameters in peripheral blood test following a regular nigh sleep and compared with a test performed following a night shift in which they slept less than 3 hours.

Each participant will serve as its own control.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Overall Study Design and Plan

  1. Subjects will be bled on the day of the experiment between 8and 9 AM.
  2. Blood tubes will be tested for T cell markers, serum cytokines levels, and other immune parameters by western blots.
  3. The first tube will be tested on the day of experiment.
  4. The second tube will kept in the lab and will be tested 24 hours later.
  5. The third tube will be kept in the pocket of the subject and be tested 24 hours later.
  6. The fourth tube will be kept in the pocket of another subject and will be tested 24 hours later.
  7. The subject will be tested again following 24 hours.
  8. Each subject will be tested twice following a regular 6-8 hours of sleep, and following an on call duty in which he slept less than 3 hours.

Study Type

Observational

Enrollment (Anticipated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Israel
      • Jerusalem, Israel, 91120
        • Hadassah Medical Organization

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 40 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Medical residnets

Description

Inclusion Criteria:

Male and female ages 18-40 signed confirmed consent no evidence of chronic disease or chronic medications

Exclusion Criteria:

Any type of acute infection or other acute illness

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Prospective

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
surface markers on T cells as assessed by FACS
Other: Blood withdrawal
Blood withdrawal

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
surface markers of T cell as assessed by FACS
Time Frame: 6 months
6 months
serum cytokine levels
Time Frame: 6 months
6 months
immune parameters to be assessed by western including STAT proteins
Time Frame: 6 months
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hadassah Medical Organization

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2013

Primary Completion (Anticipated)

September 1, 2014

Study Completion (Anticipated)

September 1, 2014

Study Registration Dates

First Submitted

August 25, 2013

First Submitted That Met QC Criteria

August 27, 2013

First Posted (Estimate)

August 28, 2013

Study Record Updates

Last Update Posted (Estimate)

August 28, 2013

Last Update Submitted That Met QC Criteria

August 27, 2013

Last Verified

August 1, 2013

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • LDB001

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe